Brief: Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart As Part Of An Immunosuppression Regimen Following Islet Transplantation In Investigator-Initiated Trial At Uchicago Medicine
29/10/2024 12:31
Oct 29 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON PHARMACEUTICALS ANNOUNCES POSITIVE INITIAL DATA
FROM
SUBJECTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS PART
OF AN IMMUNOSUPPRESSION REGIMEN FOLLOWING ISLET TRANSPLANTATION
IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE
* ELEDON PHARMACEUTICALS INC - TEGOPRUBART TREATMENT
GENERALLY
WELL TOLERATED
Source text: ID:nGNX3J1pVz
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial